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Running title: TAM and T cell epigenetic state 
Abstract 
Pancreatic Ductal Adenocarcinoma (PDA) is characterized by a complex tumor 
microenvironment that supports its progression, aggressiveness and resistance to 
therapies. The delicate interplay between cancer and immune cells creates the 
conditions for PDA development, particularly due to the functional suppression of T 
cell anti-tumor effector activity. However, some of the mechanisms involved in this 
process are still poorly understood. In this study, we analyze whether the functional 
and epigenetic profile of T cells that infiltrate PDA is modulated by the 
microenvironment, and in particular by tumor-associated macrophages (TAMs). CD4 
and CD8 T cells obtained from mice orthotopically injected with syngeneic PDA cells, 
and untreated or treated with Trabectedin, a cytotoxic drug that specifically targets 
TAMs, were sorted and analyzed by flow cytometry and characterized for their 
epigenetic profile. Assessment of cytokine production and the epigenetic profile of 
genes coding for IL10, T-bet and PD1 revealed that T cells that infiltrated PDA 
displayed activated Il10 promoter and repressed T-bet activity, in agreement with 
their regulatory phenotype (IL10high/IFNglow, PD1high). By contrast, in Trabectedin-
treated mice, PDA-infiltrating T cells displayed repressed Il10 and Pdcd1 and 
activated T-bet promoter activity, in accordance with their anti-tumor effector 
phenotype (IL10low/IFNghigh), indicating a key role of TAMs in orchestrating functions 
of PDA-infiltrating T cells by modulating their epigenetic profile towards a pro-tumoral 
phenotype. These results suggest the targeting of TAMs as an efficient strategy to 
obtain an appropriate T cell anti-tumor immune response and open new potential 
combinations for PDA treatment. 
Keywords: pancreatic cancer, tumor microenvironment, T cells, Trabectedin, 
epigenetics.
Introduction 
Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive cancers, 
having an incidence rate that almost coincides with the mortality rate, and represents 
the 5th most common cause of death due to cancer worldwide1. The 5-year survival 
rate is as low as 8% of diagnosed patients and most of them die in the first 6 months 
following diagnosis2. This is mainly due to the lack of effective markers for early 
detection, along with resistance to standard radio- and chemo-therapy3,4. 
PDA is characterized by a complex and interactive microenvironment that supports 
cancer initiation and progression, including stromal cells, cancer cells and immune 
cells5–7. For this reason, targeting components of the tumor microenvironment as a 
strategy to reduce cancer cell proliferation and survival may represent a promising 
method for overcoming resistance of pancreatic cancer cells to standard therapies. 
For many tumors, it has been demonstrated that the presence of Tumor-Infiltrating 
Lymphocytes (TILs) is associated with better prognosis8–11. In PDA as well, the 
elevated number of both infiltrating CD4 and CD8 T cells was demonstrated to 
correlate with a better outcome12. In previous studies, we have demonstrated the 
presence of T cells specific for the PDA-associated antigen alpha-enolase (ENO1), 
both in the tumor and in the blood of PDA patients13–16. More recently, we have 
described that circulating ENO1-specific T cells can represent a prognostic marker 
due to their correlation with prolonged survival17. 
The status of T cells in cancer should be considered in the context of other immune 
cells, such as Tumor-Associated Macrophages (TAMs) or Myeloid-Derived 
Suppressor Cells (MDSCs)18. Both these populations are known to create an 
immune suppressive environment through either the secretion of cytokines such as 
IL10 and TGFb, or the expression of inhibitory molecules such as PDL-119–21. This 
highly repressive environment inhibits the activation of CD8 T cells, and induces a 
switch of CD4 T cells towards T helper (Th)-2 and Treg phenotypes22,23. However, 
the presence of mixed stimuli in the microenvironment creates conditions for 
reversible changes in infiltrating cells, including TILs. These modifications derive 
from the activation or inhibition of signaling pathways and chromatin remodeling. The 
histone modification landscape is highly involved in gene transcription control and 
can be affected by several modifications, such as acetylation, methylation and 
phosphorylation24. In particular, specific histone modifications have been associated 
with gene transcription activation, such as tri-methylation of lysine 4 on histone 3 
(H3K4me3), or repression, such as tri-methylation of lysine 27 on histone 3 
(H3K27me3), and are known to rapidly change in response to environmental 
conditions25. 
Epigenetic changes in the tumor microenvironment play a central role in tumor 
initiation, progression and spreading26–29. However, despite the increasing number of 
studies investigating PDA progression and epigenetic modulation in T cells, the role 
of tumor microenvironment in the dynamic change of epigenetic modifications in 
PDA-infiltrating T cells is poorly investigated. 
In this study, we compared the phenotypic and epigenetic profile of infiltrating T cells 
in normal pancreas and PDA, with or without perturbation of the tumor stroma by 
depleting macrophages. In order to do this we exploited the selective targeting of 
mononuclear phagocytes by Trabectedin30–32. Trabectedin (ET-743, Yondelis®) was 
originally derived from Ecteinascidia turbinata33, and is currently produced semi-
synthetically. It is approved in Europe and USA as a second-line therapy for treating 
patients with advanced soft tissue sarcoma and relapsed ovarian cancers34,35. It has 
been already clarified that its antitumor effects are due to multiple mechanisms, 
namely binding to the minor groove of DNA, causing blocking of proliferation and 
different DNA repair pathways, through the transcription of p21, GADD45A and G2-
related cyclins, and inducing apoptosis via JNK and caspase 3 activation36–39. 
Trabectedin has been demonstrated to be effective against different tumor cell lines, 
and when combined with gemcitabine, the cytotoxic effects on PDA cells are 
enhanced40–42. Interestingly, Trabectedin specifically targets mononuclear 
phagocytes through activation of the caspase 8 cascade via TRAIL receptors, which 
are expressed in monocytes and TAMs43. For this reason we used Trabectedin to 
perturb the pancreatic tumor microenvironment. 
Analyzing the immune infiltrate after Trabectedin treatment revealed changes in the 
cytokine production and surface molecule expression that mirrored epigenetic 
changes in the promoter and enhancer regions of specific genes, leading to the 
rescue of the anti-tumor effector phenotype of TILs. 
In conclusion, our results indicate that targeting PDA microenvironment affects 
infiltrating T cells through epigenetic regulation, paving the way for combinatorial 
immunotherapeutic strategies.  
 
Results 
Characterization of PDA immune infiltrating cells 
K8484 murine PDA cells were orthotopically injected into the pancreata of C57BL/6 
mice. After 28 days, mice were sacrificed and tumor masses and normal pancreata 
were excised. To characterize the infiltrating cells, we enzymatically dissociated the 
pancreata and analyzed the cells by flow cytometry (Suppl. Fig. 1). A significant 
decrease of the lymphocyte population in tumors was observed in all mice, with CD4 
and CD8 T cells being reduced by 60% and 50%, respectively, compared to the 
normal pancreas (NP) (FIG. 1A left panel). Investigation of the macrophage 
population by measuring the F4/80 marker showed no differences in cell number, but 
an increased PDL-1 expression was detected in the resident macrophages 
characterized by a higher F4/80 expression44 (FIG. 1A right panels). 
Compared to the corresponding cell subsets dispersed in the NP, CD4 T cells and 
Treg cells that infiltrated PDA displayed an increased percentage of both cell type 
producing IL-10, whereas no differences were observed in the percentage of CD8 T 
cells producing this cytokine from PDA or NP (FIG. 1B upper left panel). 
Conversely, while PDA-infiltrating CD4 and CD8 T cells producing IL-17 and TNFa 
displayed no significant differences in their percentage, a decreased percentage of 
IFNg+ cells that paralleled with an increase of PD1+ cells and a decrease of CD107+ 
cells was observed for PDA-infiltrating CD8 T cells only (FIG. 1B middle and right 
panels). 
These results indicate that the PDA microenvironment plays an immunosuppressive 
role, as demonstrated by i) increased expression of PDL-1 in resident macrophages 
(F4/80hi); ii) the reduction of infiltrating CD4 T cells, which switched from a Th1 
“effector” (IFNghi/IL-10low, PD1low) to a suppressive (IFNglow/IL-10high, PD1high) 
phenotype; iii) the reduction of infiltrating CD8 T cells, which switched from an 
“effector” (IFNghi/CD107high, PD1low) to an “exhausted” (IFN-glow/CD107low, PD1high) 
phenotype and iv) the higher production of IL10 by infiltrating Treg cells. 
	PDA microenvironment affects anti-tumor immune response through epigenetic 
mechanisms 
Since phenotypic analysis of PDA immune cells showed a notable increase in Treg 
and CD4 cells producing IL10, together with a decrease in those producing IFNg, we 
investigated whether the PDA microenvironment affected epigenetic marks at the 
promoter regions of Il10 and T-bet loci; T-bet being the main transcription factor that 
induces IFN-g expression in T cells45. We sorted CD4, CD8 and Treg cells from the 
NP and PDA and measured H3K4me3, an active gene histone mark, and 
H3K27me3, a repressive mark, at the promoters of Il10 and T-bet, using chromatin 
immunoprecipitation (ChIP). In CD4 T cells from PDA, the active H3K4me3 mark 
was highly enriched at the IL10 promoter compared to the repressive H3K27me3 
mark, while equal enrichment of both marks was observed in CD4 T cells purified 
from NP (FIG. 2A left panel). In CD8 T cells, no significant differences were found 
between NP and PDA (FIG. 2A middle panel), while PDA-infiltrating Treg cells 
showed a significant decrease in the repressive mark H3K27me3 compared to the 
NP-purified ones (FIG. 2A right panel). This data corroborated the observation that 
IL10 was highly expressed by PDA-infiltrating CD4 and Treg cells, while no 
differences were observed for CD8 T cells (FIG. 1B upper right panel). 
Conversely T-bet promoter was marked by high levels of permissive H3K4me3 and 
very low levels of repressive H3K27me3 in both CD4 and CD8 T cells from NP, while 
no differences were observed for the two marks in PDA-infiltrating CD4 and CD8 T 
cells (FIG 2B), suggesting that T-bet promoter activity is modulated when T cells 
move from NP to the tumor microenvironment, affecting IFNg production. These 
results corroborated the flow cytometry data, showing that CD4 and CD8 T cells from 
NP had increased IFNg production compared to the corresponding subsets in PDA 
(FIG. 1B middle panel), and strongly suggests a role for the tumor microenvironment 
in orchestrating the immune response by an epigenetic-mediated suppression. 
 
Depletion of macrophages affects the tumor microenvironment and T cell activation 
To interfere with the tumor microenvironment, we exploited the DNA-binding anti-
tumor drug Trabectedin, which selectively induces monocyte apoptosis as a 
secondary effect30. Mice injected with K8484 tumor cells in the pancreata were 
untreated (NT) or treated intravenously on a weekly basis with Trabectedin, for three 
weeks, starting at day 7. Tumor masses were excised after 28 days and weighed 
before dissociation. Notably, Trabectedin significantly reduced tumor size (FIG. 3A 
left panel). To ascertain the efficacy of Trabectedin in depleting the monocyte 
population, we collected and analyzed blood from mice the day after every drug 
administration. Flow cytometry showed a strong decrease in circulating monocytes 
after each Trabectedin administration, while polymorphonuclear cells (PMNs) were 
not significantly affected (FIG. 3A right panel and Suppl. Fig. 2). After enzymatic 
dissociation, we analyzed the tumor-infiltrating immune cells by flow cytometry. 
Trabectedin-treated mice showed a notable decrease in CD11b+ and CD115+ 
populations (FIG. 3B left panels) and a concomitant significant increase in the 
number of infiltrating CD4 and CD8 T cells (FIG. 3B right panels). Compared with 
untreated tumor-bearing mice, the percentage of IL-10-producing CD4+ T cells and 
Treg cells was sharply decreased (FIG. 3C). A significant increase in the percentage 
of IFNg-producing cells was observed in CD4 T cells from Trabectedin-treated mice, 
while no substantial differences were observed in the percentage of IL17-producing 
or CD107+ cells in either of the T cell subsets (FIG. 3C). Notably, a sharp parallel 
increase in the percentage of Eomesodermin/Tbr2 (Eomes)+ and PD1+ cells, 
consistent with a T cell “memory” population46, was observed in CD8 T cells, but not 
in CD4 T cells, from tumor-bearing mice treated with Trabectedin (FIG. 3C). These 
results show that Trabectedin efficiently depleted monocytes, modified the tumor 
microenvironment and affected infiltrating T cells, by reducing IL10 production and 
inducing activation of CD8 T cells, as demonstrated by their “effector-memory” 
phenotype. 
 
Changes in the tumor microenvironment affect the epigenetic profile of infiltrating T 
cells	
To explore whether Trabectedin-induced changes in IL10 and IFNg production were 
caused by modifications in the epigenetic states of T cells, we sorted CD4+ and CD8+ 
T cells to analyze Il10 and T-bet promoters. We tested the permissive H3K4me3 
mark and the repressive H3K27me3 mark through ChIP analysis in untreated and 
Trabectedin-treated mice. We observed that CD4 T cells from NT mice were highly 
enriched in the permissive H3K4me3 mark, while they showed a low enrichment of 
the repressive H3K27me3 mark at the Il10 promoter. By contrast, CD4 T cells from 
Trabectedin-treated mice displayed an opposite trend, with a significant decrease in 
H3K4me3 and an increase in H3K27me3 compared to NT CD4 T cells (FIG. 4A left 
panel). These data indicate that Trabectedin changed the epigenetic state of the Il10 
promoter from an active to a silent state, corresponding to the decreased IL10 
production by CD4 T cells (FIG. 3C left panel). Conversely, both marks were weakly 
enriched in CD8 T cells from untreated mice, and enrichment of both marks 
significantly increased in CD8 T cells from Trabectedin-treated mice (FIG. 3A right 
panel). These data indicate that Trabectedin modifies the epigenetic profile of the 
Il10 promoter in CD8 T cells, although the production of IL-10 was not detectable in 
CD8 T cells from untreated mice or those treated with Trabectedin (FIG. 3C). 
Analysis of the T-bet promoter showed an enrichment of the H3K4me3 permissive 
mark and a lower enrichment of the repressive mark in CD4 T cells from untreated 
mice, whereas in mice treated with Trabectedin, CD4 T cells displayed a significant 
reduction of the permissive H3K4me3 mark without any significant changes in the 
H3K27me3 repressive mark (FIG. 4B). These variations did not predict the increased 
production of IFNg by CD4 T cells assayed by flow cytometry (FIG. 3C). No 
significant differences were observed in CD8 T cells from mice treated with 
Trabectedin compared to untreated mice, with no evident modifications in the 
H3K4me3 permissive and the H3K27me3 repressive marks of the T-bet promoter 
(FIG. 4B). This did not substantially impair their ability to produce IFNg (FIG. 3C) and 
the non-permissive regulation of T-bet could reflect a T cell phenotype skewed 
towards a “memory” status, as observed by flow cytometry analysis. 
As PD1 expression significantly increased in CD8 TILs after Trabectedin treatment 
(FIG. 3D), we investigated the methylation and acetylation states of regulatory sites 
on the Pdcd1 locus acting as enhancers located at +3.7 and -17.1 kb from the 
transcription start site47 (Suppl. FIG. 3A). In particular, we tested the active marks 
H3K4me1 and acetylation on lysine 27 of H3 (H3K27Ac), in sorted PDA-infiltrating 
CD4 and CD8 T cells from untreated or Trabectedin-treated mice through ChIP. 
Purified PDA-infiltrating CD4 T cells from Trabectedin-treated mice showed 
enrichment in H3K4me1 at both enhancers, while a slight decrease was observed for 
H3K27Ac enrichment compared to PDA-infiltrating CD4 T cells from NT mice 
(Suppl. FIG. 3B). By contrast, no changes in H3K4me1 enrichment, but a significant 
decrease in H3K27Ac enrichment for both +3.7 and -17.1 enhancers was observed 
in PDA-infiltrating CD8 T cells from Trabectedin-treated mice compared to PDA-
infiltrating CD8 T cells from NT mice. These results do not fully correspond with the 
flow cytometry results, and suggest that PD1 up-regulation on CD8 TILs after 
Trabectedin treatment is independent from these two enhancers. Therefore, other 
enhancers may play a role in the regulation of PD1 expression, or Trabectedin may 
affect different pathways inducing PD1 expression.  
 
Effect of Trabectedin on epigenetics of CD4 T cells is both direct and macrophage-
mediated  
To confirm whether the effect of Trabectedin on PDA-infiltrating CD4 T cells was 
direct or mediated by the depletion of macrophages, we sorted CD4 T cells from 
normal mice and cultured them in the presence or absence of Trabectedin and in the 
presence or absence of supernatants from bone marrow-derived macrophages 
previously untreated or treated with Trabectedin. We chose CD4 T cells, as they 
were the most regulated in all three promoters. ChIP analysis of the Il10 promoter 
revealed a consistent decrease in H3K4me3 upon Trabectedin treatment in CD4 T 
cells cultured in medium only, and to a much greater extent in those cultured in the 
presence of macrophage supernatants (FIG. 5A). This suggests that Trabectedin 
directly and negatively regulates IL10 production, which is amplified by the presence 
of macrophage-secreted factors. By contrast, ChIP analysis of the T-bet promoter 
showed a significant increase of both epigenetic marks only in stimulated CD4 T 
cells with the supernatants of macrophages cultured in the presence of Trabectedin 
(FIG. 5B). Enrichment of the repressive H3K27me3 mark confirms the ex-vivo 
epigenetic data shown in FIG. 4, but the specific increase in H3K4me3 in CD4 cells 
cultured with the supernatants of Trabectedin-treated macrophages suggests a role 
of the latter in mediating the epigenetic switch in T cells. Finally, analysis of the 
Pdcd1 promoter revealed enrichment in H3K27me3 only when CD4 T cells were 
cultured in the presence of Trabectedin-treated macrophage supernatants (FIG. 5C). 
Further analysis of histone modifications associated with active enhancers, 
H3K4me1 and H3K27Ac, in the -3.7 kb enhancer region of Pdcd1 locus, 
demonstrated a decrease induced by Trabectedin in both the epigenetic marks when 
T cells were treated in the presence of macrophage supernatants, while the opposite 
was observed for T cells alone (FIG. 5D upper panels). Analysis of the +17.1 kb 
genomic region revealed a strong enrichment for both marks in CD4 T cells 
stimulated with Trabectedin-treated macrophage supernatants (FIG. 5D lower 
panels). These results suggest that Trabectedin may have a direct effect on T cells, 
but the presence of macrophages enhances this effect, promoting an epigenetic 
switch that changes their functions. 
 
Trabectedin changes the macrophage secretome  
To further investigate the effect of Trabectedin on macrophages and the indirect 
effect on TILs, we performed a cytokine array with the conditioned supernatant used 
in Figure 5 (FIG. 6). Trabectedin significantly up-regulated 17 cytokines/chemokines, 
and down-regulated CCL12 only. Among the statistically significant up-regulated 
there are IL2, IL12, IL17 and TNFα, which are involved in T cell activation. Moreover, 
Trabectedin increased the expression of granulocyte- and granulocyte and monocyte 
colony stimulator factors (G-CSF and GM-CSF) and some chemokines as CCL27, 
CCL11 and CXCL1, which elicit the recruitment of memory T cells to inflammatory 
sites and neutrophil activation, respectively48,49. Overall, these results suggest that 
Trabectedin induces an increase in inflammatory cytokine and chemokine production 
by macrophages, which shapes and regulates the epigenetic landscape of specific 
promoters related to the activation and phenotype of T cells. 
 
Discussion 
Despite the continuous advances in cancer research, PDA remains one of the most 
challenging tumors to diagnose and treat2. In this study, we focused on the complex 
interplay occurring in the tumor microenvironment in order to clarify mechanisms 
involved in the suppression of the immune response, with particular attention to the 
epigenetic profile of infiltrating T cells. 
Tumors engage the immune system from their inception. Initially, cells of the innate 
system such as macrophages and mast cells are mainly involved. However, even at 
early stages, cells of the acquired system are engaged, particularly T cells50. Recent 
data have challenged the original idea that PDA is poorly immunogenic. Above all, 
higher levels of tumor-infiltrating CD4 and CD8 lymphocytes and dendritic cells 
positively correlate with longer survival after surgical resection12. We have also 
described that PDA-infiltrating T cells specifically recognize alpha-enolase (ENO1), a 
PDA-associated antigen14, but are often frustrated in their effector functions by the 
presence of Tregs15. Of note, peripheral ENO1-specific T cells mirror the intra-
tumoral immune response and represent a promising candidate as a prognostic 
marker of survival17. 
Here, we analyzed PDA-infiltrating T cells to define their functional states and how 
they were reflected in their epigenetic landscape. Although some studies have 
addressed the question of the number of PDA-infiltrating T cells12, to our knowledge 
this is the first study that characterizes the epigenetic states of PDA-TILs. Here, we 
demonstrated that CD4 and CD8 T cells accumulated to a lesser extent in the PDA 
compared to the normal pancreata, while no differences were observed in either 
CD11b/F4/80hi or CD11b/F4/80low myeloid cells. Of note, PDL-1 expression was 
increased in both CD11b/F4/80low and CD11b/F4/80hi myeloid cells, but especially in 
the latter. PDA-infiltrating T cells, especially CD4 and Tregs, highly produced IL-10 
but not IFNg, while there were no differences in those producing IL-17 or TNFa. 
Even PD1 was substantially increased on CD8 T cells, confirming that inflammation 
that was strictly associated with PDA growth led to activation of both types of T cells, 
but they were eventually restrained by the regulatory and suppressor immune cells. 
In addition, our results showed that the PDA microenvironment also induced 
alterations in the epigenome of the TILs, probably by means of soluble and cell-
contact factors. These effects can be generally promoted by different, extremely 
heterogeneous cell types in the microenvironment, and we focused on TAMs, which 
are well-known pro-tumor cells that suppress anti-tumor responses through the 
secretion of cytokines, chemokines and exposure of inhibitory ligands51,52. Targeting 
myeloid cells to limit T cell suppression and induce efficient anti-tumor responses 
has been used as a strategy in many tumors, includingPDA53,54, employing different 
drugs55–57. Depletion of GM-CSF or Gr1+CD11b+ myeloid cells has been described 
as being sufficient to inhibit implanted PDA cells and efficiently recruit CD8 T cells, 
which are responsible for tumor growth impairment, as their depletion can restore 
tumor growth39,54. 
We exploited Trabectedin, a drug known to affect both tumor cells and TAMs39. 
Trabectedin has been demonstrated to be active in inducing cell cycle arrest or 
cytotoxicity on a variety of tumor cells and can selectively inhibit the transcription of 
different pro-inflammatory factors and angiogenic mediators by macrophages42. After 
Trabectedin-dependent TAM deprivation, TILs showed a reactivation both at the 
epigenetic and functional levels, with a switch from IL10-secreting T cells towards an 
effector/memory phenotype, as demonstrated by the increased percentage of IFNg+ 
and Eomes+ T cells. The changes in the secretome of TAMs after Trabectedin 
treatment suggests that this switch could be partly mediated by inflammatory 
cytokines and chemokines secreted in response to the treatment. PD1+ CD8 T cells 
are increased in Trabectedin-treated mice compared to PDA-infiltrating CD8 T cells 
from untreated mice, and to a lesser extent in CD4 T cells. This confirms their 
activation status, as PD1 is increased by T cell activation58. After activation of T cell 
receptors, T cells start to actively secrete cytokines (such as IFN-γ in our study) and 
express PD1, together with the costimulatory receptor CD28, its early and 
preferential target59,60. After prolonged antigen stimulation, the T cells become 
“exhausted” but still express PD1. Of note, the epigenetic results did not 
demonstrate an active transcription, as shown by the protein expression after 
Trabectedin treatment. Thus, other regulatory regions or signaling pathways seem to 
be involved in the complex expression of PD1. However, Trabectedin acts on both 
sides, i.e. tumor cells and immune cells, by inducing cell death and triggering an 
efficient anti-tumor response, respectively. These results demonstrate that modifying 
the microenvironment composition also affects immune infiltrating cells, not only in 
terms of numbers, but also by inducing a shift in their activation profiles. However, 
additional studies are needed to provide further evidence of the role of 
macrophages, by exploiting a genetic macrophage-depleted mouse model. In 
addition, in vitro experiments suggest a direct effect of Trabectedin on T cells, 
proposing a new target for this drug that deserves further investigation. 
Overall, this study demonstrates that PDA-infiltrating T cells are epigenetically 
shaped by the microenvironment, and particularly by TAMs. The use of Trabectedin 
to perturb the composition of the microenvironment by depleting TAMs, and their 
anti-tumoral effects, opens new options for novel combinatorial therapies. Among 
treatments involving active immunotherapy, Trabectedin has been successfully 
tested in combination with anti-PD1 antibody in ovarian cancer61, and its combination 
with doxorubicin has been shown to be effective in a phase 2 clinical trial in 
leyomiosarcoma35. Regarding the combination with PD1 treatment, our results 
suggest that the timing of this combination can be essential. Indeed, Trabectedin 
treatment is able to modulate chromatin remodeling in specific genomic regulatory 
regions in the Pdcd1 locus, and consequently PD1 expression on T cells.  
Taking into account the major role played by chromatin remodeling in the PDA 
microenvironment, new therapeutic strategies deploying epigenetic modulating 
agents also need to be considered for PDA. Some epigenetic drugs have been 
already tested in PDA with promising results62, but no effects on immune infiltrating 
cells have been described. In particular, inhibition of histone methyltransferases, by 
Enhancer Of Zeste Homolog (EZH) 2 or histone deacetylases (HDACs), significantly 
impaired PDA progression, with EZH2 interfering with the oncogenic activity of 
NFATC1 and HDACs promoting epithelial gene expression63–66, but there is no 
mention about their effect on TILs.  
The most common opinion is that a successful anti-cancer therapy should exploit the 
combinatorial treatment of several targets in the microenvironment, from cancer cells 
to immune or stromal cells. Due to the strong interconnection between cell-type 
specific responses to the environment and the epigenetic profile, as well as the 
increasing number of drugs affecting epigenetic regulators, new molecular targets 
are constantly being identified. Perturbing the right components with combinatorial 
therapies may open new effective ways to fight PDA. 
 
Materials and methods 
Cell Culture  
The murine pancreatic cancer cell line K8484 was obtained from mice carrying 
mutated KrasG12D and Trp53R172H (kindly provided by Dr. K. Olive, Columbia 
University). Cell lines were cultured in DMEM (Lonza, 12-719F) supplemented with 
10% FBS (Gibco, 10500056), L-Glutamine (GE Healthcare, SH30034.01) and 
50µg/ml of gentamicin (Gentalyn 40mg/ml, Essex Italia) at 37°C in a 5% CO2 
atmosphere. Cells were detached using a solution of PBS (Lonza, 17-516F) 
containing 0.25% Trypsin-EDTA (Gibco, 15400054). Before injection, cells were 
washed twice with PBS and re-suspended in DMEM without FBS. 
In vivo experiments 
All animal experiments were approved by the University of Torino, Italian Ministry of 
Health and performed in accordance with EU laws in the animal facility of the 
Molecular Biotechnology Center (MBC). 
C57BL/6 mice were anesthetized and orthotopically injected into the pancreas with 
1x105 K8484 cells resuspended in DMEM with Matrigel (BD Bioscience, 354234) at 
a dilution of 1:4. After 28 days, mice were euthanized; PDA were weighed and the 
tumor masses and normal pancreata were separated. To avoid the presence of 
peripheral blood cells in the pancreas, mice were intracardially perfused with 10 ml 
PBS. Trabectedin was administered every 7 days intravenously into the tail vein of 
the mice at 0.015 mg/kg in physiologic solution. Age-matched mice were randomly 
assigned to the control group, in which mice were injected with the same volume of 
PBS, or the treated group. The day following drug administration, 30µl of peripheral 
blood was collected to analyze monocyte and polymorphonuclear cells by flow 
cytometry. 
Trabectedin was provided as a lyophilized formulation by PharmaMar (S.A. 
Colmenar Viejo), dissolved in DMSO and stored at -20°C. 
Tissue dissociation 
Tumors and normal pancreata were enzymatically dissociated with a cocktail 
containing Collagenase IV (Sigma-Aldrich, C5138), Hyaluronidase V (Sigma-Aldrich, 
H5264), Dispase II (Roche, 04942078001), DNAse I (Millipore, 200913) and 
Soybean Trypsin Inhibitor (Worthington Biochemical, LS003587). Tumors and 
normal pancreata from three mice were pooled for analysis. Cells were filtered 
through 70 µm and 40 µm cell strainers to obtain a cell mono-suspension. Cells were 
analyzed immediately or after 12h of stimulation with PMA (Sigma-Aldrich, P-1585), 
Ionomycin (Sigma-Aldrich, I3909) and Brefeldin A (BioLegend, 420601), by flow 
cytometry. 
Flow cytometry analysis and cell sorting 
A total of 1x105 dissociated cells per tube were washed twice with PBS-0.2% BSA-
0.01% NaN3. After blocking nonspecific sites with anti-CD16/CD32 mAb 
(MiltenyiBiotec, 130-092-574), cells were incubated with mAbs for 30 min at 4°C: 
FITC anti-mouse CD4 (MiltenyiBiotec, 130-102-779), PerCP anti-mouse CD8a 
(MiltenyiBiotec, 130-102-811), APC anti-mouse CD8a (eBioscience, 17-0081-81), 
PE anti-mouse CD19 (Biolegend, 151407), PE anti-mouse CD25 (Biolegend, 
101903), PE anti-mouse PDL-1 (Biolegend, 124307), PerCP anti-mouse F4/80 
(Biolegend, 123125), APC anti-mouse CD127 (MiltenyiBiotec, 130-102-551), PE 
anti-mouse IL-10 (MiltenyiBiotec, 130-103-014), PE anti-mouse PD-1 (MiltenyiBiotec, 
130-11-953), PE anti-mouse CD107 (MiltenyiBiotec, 130-102-219), APC anti-mouse 
IFNg (MiltenyiBiotec, 130-102-340), FITC anti-mouse CD11b (eBioscience, 11-0112-
82). Intracellular staining was performed with Foxp3/Transcription Factor Staining 
Buffer Set (eBioscience, 00-5523-00) using APC anti-mouse FoxP3 antibody 
(eBioscience, 17-5773-80). Cells were washed, re-suspended in PBS and acquired 
with a BD AccuriC6 Flow Cytometer (BD). Analysis was performed using FlowJo 7.5 
software for tissue analysis and using BD Accuri C6 software for blood analysis. 
For cell sorting, cells were blocked with a short incubation with anti-CD16/CD32 mAb 
and stained with FITC anti-mouse CD4, PerCP anti-mouse CD8a and APC anti-
mouse CD127 for 30 min at 4°C. After washing, cells were resuspended with PBS-
2mM EDTA-2% BSA and sorted with a FACSAria III and data were analyzed through 
BD FACSDiva software 7.0 (both by BD). 
Chromatin Immunoprecipitation Assay (ChIP)  
Lymphocytes purified from tissues were incubated with 1% formaldehyde in PBS for 
10 min at 37°C. The crosslinking reaction was stopped by adding glycine at a final 
concentration of 125 mM, and samples were incubated for 5 min at Room 
Temperature (RT). Crosslinked cells were then resuspended in 25µl of Lysis buffer 
(50mM Tris-HCl pH 8,10mM EDTA and 1% SDS). Cell lysates were incubated on ice 
for 10min, diluted with 75 µl Immuno-Precipitation (IP) buffer (16.7mMTrisHCl pH 8, 
167mMNaCl, 1.2mM EDTA, 0.01% SDS and 1.1% Triton X-100), and then sonicated 
for 30 pulse 30″ON/30″OFF high with Bioruptor Twin (Diagenode). The protocol 
required the use of a small amount of chromatin and was modified from ref. 67. 
Sonicated chromatin was diluted in IP buffer to a final volume of 120µl for each 
immunoprecipitation, and incubated with 0.5µg of antibodies against human 
H3K4me3, H3K27me3, H3K4me1 or H3K27ac (ActiveMotif; 39915, 39155, 61633 or 
39133) in a BSA pre-treated 96-well dish. Lysates with Ab were incubated at 4°C 
overnight on an orbital shaker. Samples with IgG antibody (Santa Cruz 
Biotechnology, sc-2027) were run in parallel as negative controls. The following day, 
30µl of 50% Protein A SepharoseTM 4 Fast Flow slurry (GE Healthcare, 17-5280-01) 
was added and incubated for 2 h at 4°C to purify the immune complexes. Proteins 
and DNA complexes not specifically associated with beads were removed by 
sequential washes with low-salt buffer (0.1%SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl pH8 and 150mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20mM Tris-HCl, pH8.0 and 500mM NaCl), LiCl washing buffer 
(0.25M LiCl; 1% deoxycholate sodium salt, 1mM EDTA, 10mMTris-HCl pH8.0 and 
1% NP-40) and twice with Tris-EDTA buffer (10mMTris-HCl pH8, 1mM EDTA). 
Samples were maintained at 4°C for 5 min per wash. The immunoprecipitated DNA-
protein complexes were purified using 10% Chelex® 100 Resin (BioRad, 142-2822) 
for 10 min at 95°C. Proteins were digested by incubating each sample with 20µg of 
Proteinase K (Thermo Fisher Scientific, AM2546) for 30 min at 55°C and then 10 min 
at 95°C to obtain Proteinase K inactivation, thus achieving DNA purification. 
Oligonucleotide primer sequences used for quantification of enriched DNA after 
chromatin immunoprecipitation are listed in Supplementary Materials & Methods 
(Suppl. Table 1). 
T cell conditioning with macrophage-derived supernatants 
CD11b cells were magnetically purified from spleens from tumor-bearing mice 
following the manufacturer’s instructions (MiltenyiBiotec, 130-047-142), and 2x106 
cells/ml were cultured in the presence of 25 ng/ml of murine M-CSF (MiltenyiBiotec, 
130-101-706) in a 6-well plate for 4 days at 37°C. After washing with RPMI only, 
macrophages were incubated in the presence or absence of Trabectedin (0.05 
µg/ml) for 24 h. Supernatants were collected and frozen at -20°C until use. 
CD4 T cells were sorted from splenocytes from naïve C57BL/6 mice, as described 
above, and cultured in the presence or absence of supernatants from untreated or 
treated macrophages, and in the presence or absence of Trabectedin (0.05 µg/ml) 
for 24 h at 37°C. After two washes, cells were harvested and processed as 
described for ChIP. 
 
Cytokine array 
Supernatants from macrophages treated with Trabectedin (0.05 µg/ml) for 24 h, or 
untreated, were evaluated for the presence of chemokines/cytokines with the Mouse 
Cytokine array C2 (RayBiotech, AAM-CYT-2-2). The arrays were performed 
according to the manufacturer’s instructions. Pictures were acquired with the 
ProXpress 2D Proteomic Imaging System and saved as .tiff images (PerkinElmer, 
Milan, Italy). Spot volumes were analyzed using the ProFinder software 
(PerkinElmer). To determine the relative presence of cytokines/chemokines induced 
by the presence of Trabectedin, each sample was normalized according to values 
obtained from untreated cells. 
 
Statistical Analysis 
The Student’s t test (GraphPad Prism 5 Software) was used to evaluate statistically 
significant differences in in vitro and in vivo experiments. Values are expressed as 
means ± SEM. * p<0.05, ** p<0.01, *** p<0.001 
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Figure legends 
 
Figure 1. Phenotypic analysis of PDA immune infiltrating cells. 
(A) Characterization of T cells and F4/80 positive and negative populations in normal 
pancreas (NP) versus PDA. PDL-1 expression on F4/80hi and F4/80low cells is shown 
as delta Geo Mean of the fluorescence intensity after subtraction of isotype-related 
values. (B) Analysis of cytokine production and surface marker expression in NP or 
PDA-infiltrating T cells. Each graph shows the percentage of positive cells for the 
specific marker as indicated on the Y-axis. Data are represented as mean ± SEM of 
pooled cells from three independent experiments with two/three mice per 
experiment. Statistical analysis by unpaired Student’s t test. 
 
Figure 2. Epigenetic changes of Il10 and T-bet promoters in PDA-infiltrating T 
cells. 
(A) ChIP analysis targeting H3K4me3 and H3K27me3 at Il10 promoter in CD4, CD8 
and Treg cells sorted from NP and PDA. (B) ChIP analysis targeting H3K4me3 and 
H3K27me3 at T-bet promoter in CD4 and CD8 T cells sorted from NP and PDA. 
Columns represent the percentage of input chromatin. Data are represented as 
mean ± SEM of pooled cells from two independent experiments with three mice per 
experiment, in which tumor cell suspensions were pooled together for the sorting. 
Statistical analysis by unpaired Student’s t test. *, **, *** P values statistically 
different between NP and PDA; §§§ P values statistically different between 
permissive and repressive marks in the NP group. 
 
Figure 3. Phenotypic analysis of the PDA microenvironment after Trabectedin 
treatment. 
(A) Left panel: PDA wet weight from untreated (NT) and Trabectedin-treated (Tra) 
mice. Data are represented as box and whiskers of Tukey’s method (six mice per 
group; statistical analysis by unpaired Student’s t test). Right panel: Flow cytometry 
analysis of Monocytes (MÆ) and Polymorphonuclear cells (PMN) in blood collected 
24 h after each Trabectedin treatment from NT and Trabectedin-treated mice. (B) 
Absolute number of infiltrating immune cells positive for specific markers, expressed 
per 104 leukocytes from NT and Trabectedin-treated mice. (C) Analysis of PDA-
infiltrating T cell cytokine production and surface markers from NT or Trabectedin-
treated mice. Each plot shows the percentage of positive cells for the specific 
marker, as indicated on the Y-axis. Data are represented as means ± SEM of pooled 
cells from two independent experiments with three mice per condition. Statistical 
analysis by unpaired Student’s t test. 
	
Figure 4. Epigenetic changes of Il10 and T-bet promoters in PDA-infiltrating T 
cells after Trabectedin treatment. 
ChIP analysis targeting H3K4me3 and H3K27me3 of (A) Il10 and (B) T-bet 
promoters in PDA-infiltrating CD4 and CD8 T cells sorted from NT and Trabectedin-
treated mice. Columns represent percentage of input chromatin. Data are 
represented as means ± SEM of pooled cells from two independent experiments, in 
which tumor cell suspensions from three mice were pooled together for the sorting. 
Statistical analysis by unpaired Student’s t test. *, ** P values statistically different 
between NT and Tra; §, §§ P values statistically different between permissive and 
repressive marks in the NT or Tra group. 
 
Figure 5. Effects of Trabectedin on CD4 T cells. 
ChIP analysis of H3K4me3 and H3K27me3 of Il10 (A) and T-bet (B) and Pdcd1 
promoter (C) and associated enhancers at -3.7 kb and +17.1 kb from the 
transcription start site (D) in sorted CD4 T cells from naïve mice alone or in the 
presence of Trabectedin and stimulated with supernatants from MÆ in the presence 
or absence of Trabectedin. Columns represent percentage of input chromatin.  
Data are represented as means ± SEM of pooled cells from two independent 
experiments. Statistical analysis by unpaired Student’s t test. *, **, *** P values 
statistically different between NT and Tra; §, §§ P values statistically different between 
permissive and repressive marks in the NT or Tra group. 
	
Figure 6. Evaluation of chemokine/cytokine secretion by macrophages after 
Trabectedin treatment. 
(A) Quantification of cytokines and chemokines in the supernatants of macrophages 
treated with Trabectedin for 24 h, or untreated. Data are represented as means of 
normalized volumes (arbitrary units - AU) ± SEM from two independent experiments. 
Statistical analysis by unpaired Student’s t test. (B) Representative spots from the 
recorded images of one array. 
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